Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19

The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment wil...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Case Rep
Autori principali: Khatib, Mohamad Y., Shaik, Karimulla S., Ahmed, Amna A., Alwraidat, Mohammad A., Mohamed, Ahmed S., Abou Kamar, Mohamad R., Sharaf Eldean, Mouhammad Z., Aldaraiseh, Bashar K., Nashwan, Abdulqadir J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Case Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7813092/
https://ncbi.nlm.nih.gov/pubmed/33489151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3487
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi